复发多发性骨髓瘤治疗的最新进展:对治疗决策的启示
综述探讨新型药物在复发多发性骨髓瘤中的应用证据,重点分析在来那度胺联合地塞米松方案基础上加用卡非佐米、伊沙佐米、埃罗妥珠单抗或达雷妥尤单抗的三药联合数据,以及在硼替佐米联合地塞米松方案基础上加用帕比司他、埃罗妥珠单抗或达雷妥尤单抗的数据。作者承认缺乏头对头比较数据,仍汇总最新数据以提供临床决策依据。
要点
- 来那度胺联合地塞米松基础上可加用卡非佐米、伊沙佐米、埃罗妥珠单抗或达雷妥尤单抗。
- 硼替佐米联合地塞米松基础上可加用帕比司他、埃罗妥珠单抗或达雷妥尤单抗。
- 缺乏头对头比较数据,临床决策需基于现有最新数据综合判断。
核心结论
- 新型药物对复发多发性骨髓瘤治疗有潜在重要影响,但缺乏头对头比较数据,需汇总最新数据为临床决策提供依据。
研究设计与样本
- 综述,检索并汇总临床试验中新型药物用于复发多发性骨髓瘤的证据。
主要发现
- 支持在来那度胺联合地塞米松基础上加用卡非佐米、伊沙佐米、埃罗妥珠单抗或达雷妥尤单抗的数据。
- 支持在硼替佐米联合地塞米松基础上加用帕比司他、埃罗妥珠单抗或达雷妥尤单抗的数据。
- 承认缺乏头对头比较数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏头对头比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The availability of novel therapies for the treatment of multiple myeloma has had a dramatic impact on the depth of response that can be expected on initial treatment. Despite these advances, disease relapse remains inevitable in most patients and brings with it a different set of priorities for therapy. The most recent wave of novel agents may have a particular impact in the relapsed setting. In this review, we examine the evidence currently available from clinical trials for the use of novel agents, particularly in the formation of triplet therapy. We consider data supporting the addition of the proteasome inhibitors carfilzomib and ixazomib, or the monoclonal antibodies elotuzumab or daratumumab, to a treatment backbone of lenalidomide and dexamethasone. The clinical data set is less well developed for the addition of a third agent to the combination of bortezomib and dexamethasone; nonetheless, data are presented supporting the addition of the histone deacetylase inhibitor panobinostat, or elotuzumab or daratumumab. While acknowledging the lack of head-to-head data on which to base comparisons between the numerous regimens, we collate the latest data in order to provide a basis on which to make clinical decisions in this rapidly advancing field.
引用
- Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. Br J Haematol. 2017. PMID: 28556890. doi:10.1111/bjh.14780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。